Quantcast
Home > Quotes > REPL

Replimune Group, Inc. Common Stock (REPL) Quote & Summary Data

REPL 
$14.045
*  
0.245
1.78%
Get REPL Alerts
*Delayed - data as of Nov. 16, 2018  -  Find a broker to begin trading REPL now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    REPL Pre-Market
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
N/A / N/A
1 Year Target
26
Today's High / Low
$ 14.55 / $ 12.89
Share Volume
31,831
50 Day Avg. Daily Volume
71,680
Previous Close
$ 13.80
52 Week High / Low
$ 23.55 / $ 10.52
Market Cap
443,171,323
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
0

Intraday Chart

Shares Traded

Share Volume:
31,831
50 Day Avg. Daily Volume:
71,680

Trading Range

The current last sale of $14.045 is 33.51% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 14.55 $ 23.55
 Low: $ 12.89 $ 10.52

Company Description (as filed with the SEC)

We are a clinical-stage biotechnology company committed to applying our leading expertise in the field of oncolytic immunotherapy to transform the lives of cancer patients. We use our proprietary Immulytic platform to design and develop product candidates that are intended to maximally activate the immune system against cancer. We are currently conducting a Phase 1/2 clinical trial with our lead product candidate, RP1, in approximately 150 patients with a range of solid tumors. We have entered into a collaboration with Bristol-Myers Squibb Company, or BMS, under which it has granted us a non-exclusive, royalty-free license to, and is supplying at no cost, its anti-PD-1 therapy, nivolumab, for use in combination with RP1 in this clinical trial. BMS has no further development-related obligations under this collaboration.  ... More ...  


Risk Grade

Where does REPL fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 13.66
Open Date:
Nov. 16, 2018
Close Price:
$ 13.80
Close Date:
Nov. 16, 2018

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x